Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes

Paul W. Burridge, Elias Zambidis

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes are a novel source of cells for patient-specific cardiotoxicity drug testing, drug discovery, disease modeling, and regenerative medicine. We describe a versatile and cost-effective protocol for in vitro cardiac differentiation that is effective for a wide variety of hiPSC and human embryonic stem cell (hESC) lines. This highly optimized protocol produces contracting human embryoid bodies (hEB) with a near total efficiency of 94.7 ± 2.4% in less than 9 days, and minimizes the variability in cardiac differentiation commonly observed between various hiPSC and hESC lines. The contracting hEB derived using these methods contain high percentages of pure functional cardiomyocytes, highly reproducible electrophysiological profiles, and pharmacologic responsiveness to known cardioactive drugs.

Original languageEnglish (US)
Title of host publicationMethods in Molecular Biology
Pages149-161
Number of pages13
Volume997
DOIs
StatePublished - 2013

Publication series

NameMethods in Molecular Biology
Volume997
ISSN (Print)10643745

Fingerprint

Induced Pluripotent Stem Cells
Cardiac Myocytes
Embryoid Bodies
Human Body
Cell Line
Regenerative Medicine
Drug Discovery
Pharmaceutical Preparations
Costs and Cost Analysis
Human Embryonic Stem Cells

Keywords

  • Cardiac
  • Cardiomyocyte
  • Differentiation
  • Forced aggregation
  • Heart
  • Human embryonic stem cell
  • Induced pluripotent stem cell

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics

Cite this

Burridge, P. W., & Zambidis, E. (2013). Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes. In Methods in Molecular Biology (Vol. 997, pp. 149-161). (Methods in Molecular Biology; Vol. 997). https://doi.org/10.1007/978-1-62703-348-0_12

Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes. / Burridge, Paul W.; Zambidis, Elias.

Methods in Molecular Biology. Vol. 997 2013. p. 149-161 (Methods in Molecular Biology; Vol. 997).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Burridge, PW & Zambidis, E 2013, Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes. in Methods in Molecular Biology. vol. 997, Methods in Molecular Biology, vol. 997, pp. 149-161. https://doi.org/10.1007/978-1-62703-348-0_12
Burridge PW, Zambidis E. Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes. In Methods in Molecular Biology. Vol. 997. 2013. p. 149-161. (Methods in Molecular Biology). https://doi.org/10.1007/978-1-62703-348-0_12
Burridge, Paul W. ; Zambidis, Elias. / Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes. Methods in Molecular Biology. Vol. 997 2013. pp. 149-161 (Methods in Molecular Biology).
@inproceedings{8df1749ca7a04e9f8fb9c5e3ca33b428,
title = "Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes",
abstract = "Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes are a novel source of cells for patient-specific cardiotoxicity drug testing, drug discovery, disease modeling, and regenerative medicine. We describe a versatile and cost-effective protocol for in vitro cardiac differentiation that is effective for a wide variety of hiPSC and human embryonic stem cell (hESC) lines. This highly optimized protocol produces contracting human embryoid bodies (hEB) with a near total efficiency of 94.7 ± 2.4{\%} in less than 9 days, and minimizes the variability in cardiac differentiation commonly observed between various hiPSC and hESC lines. The contracting hEB derived using these methods contain high percentages of pure functional cardiomyocytes, highly reproducible electrophysiological profiles, and pharmacologic responsiveness to known cardioactive drugs.",
keywords = "Cardiac, Cardiomyocyte, Differentiation, Forced aggregation, Heart, Human embryonic stem cell, Induced pluripotent stem cell",
author = "Burridge, {Paul W.} and Elias Zambidis",
year = "2013",
doi = "10.1007/978-1-62703-348-0_12",
language = "English (US)",
isbn = "9781627033473",
volume = "997",
series = "Methods in Molecular Biology",
pages = "149--161",
booktitle = "Methods in Molecular Biology",

}

TY - GEN

T1 - Highly efficient directed differentiation of human induced pluripotent stem cells into cardiomyocytes

AU - Burridge, Paul W.

AU - Zambidis, Elias

PY - 2013

Y1 - 2013

N2 - Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes are a novel source of cells for patient-specific cardiotoxicity drug testing, drug discovery, disease modeling, and regenerative medicine. We describe a versatile and cost-effective protocol for in vitro cardiac differentiation that is effective for a wide variety of hiPSC and human embryonic stem cell (hESC) lines. This highly optimized protocol produces contracting human embryoid bodies (hEB) with a near total efficiency of 94.7 ± 2.4% in less than 9 days, and minimizes the variability in cardiac differentiation commonly observed between various hiPSC and hESC lines. The contracting hEB derived using these methods contain high percentages of pure functional cardiomyocytes, highly reproducible electrophysiological profiles, and pharmacologic responsiveness to known cardioactive drugs.

AB - Human-induced pluripotent stem cell (hiPSC)-derived cardiomyocytes are a novel source of cells for patient-specific cardiotoxicity drug testing, drug discovery, disease modeling, and regenerative medicine. We describe a versatile and cost-effective protocol for in vitro cardiac differentiation that is effective for a wide variety of hiPSC and human embryonic stem cell (hESC) lines. This highly optimized protocol produces contracting human embryoid bodies (hEB) with a near total efficiency of 94.7 ± 2.4% in less than 9 days, and minimizes the variability in cardiac differentiation commonly observed between various hiPSC and hESC lines. The contracting hEB derived using these methods contain high percentages of pure functional cardiomyocytes, highly reproducible electrophysiological profiles, and pharmacologic responsiveness to known cardioactive drugs.

KW - Cardiac

KW - Cardiomyocyte

KW - Differentiation

KW - Forced aggregation

KW - Heart

KW - Human embryonic stem cell

KW - Induced pluripotent stem cell

UR - http://www.scopus.com/inward/record.url?scp=84877078624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877078624&partnerID=8YFLogxK

U2 - 10.1007/978-1-62703-348-0_12

DO - 10.1007/978-1-62703-348-0_12

M3 - Conference contribution

C2 - 23546754

AN - SCOPUS:84877078624

SN - 9781627033473

VL - 997

T3 - Methods in Molecular Biology

SP - 149

EP - 161

BT - Methods in Molecular Biology

ER -